Gill J S, Al-Hussary N, Zezulka A V, Pasi K J, Atkins T W, Beevers D G
Clin Ther. 1987;9(3):304-10.
The hypothesis that nifedipine may cause an insidious but reversible change in glucose tolerance, similar to that associated with thiazide therapy, was studied in six nondiabetic and six noninsulin-dependent diabetic patients with hypertension. After medium-term nifedipine therapy (mean duration, 11.5 months) was stopped for one month and then resumed for a month, values for fasting blood glucose, fasting serum insulin, serum fructosamine, glucose tolerance, and insulin release in response to oral glucose were unchanged in both groups. These findings suggest that nifedipine in conventional doses does not have important effects on glucose handling in either diabetic or nondiabetic patients.
硝苯地平可能会引起糖耐量隐匿但可逆的变化，类似于噻嗪类药物治疗相关的变化，这一假说在6名非糖尿病和6名非胰岛素依赖型高血压糖尿病患者中进行了研究。在硝苯地平中期治疗（平均疗程11.5个月）停药1个月后再恢复治疗1个月后，两组患者的空腹血糖、空腹血清胰岛素、血清果糖胺、糖耐量以及口服葡萄糖后的胰岛素释放值均未改变。这些发现表明，常规剂量的硝苯地平对糖尿病或非糖尿病患者的血糖处理没有重要影响。
